Cutis laxa in hereditary gelsolin amyloidosis

British Journal of Dermatology

Volumn 152, Issue 2, 2005, Pages 250-257

  Kiuru Enari, S ^a   Keski Oja, J ^a   Haltia, M ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Amyloid; Cutis laxa; Elastic fibres; Gelsolin; Genodermatosis; Hereditary amyloidosis

Indexed keywords

AMYLOID P COMPONENT; GELSOLIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CUTIS LAXA; DISEASE ASSOCIATION; ELASTIC FIBER; FAMILIAL AMYLOIDOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SKIN BLOOD VESSEL; SKIN NERVE; SKIN STRUCTURE;

ADULT; AGED; AMYLOIDOSIS, FAMILIAL; CUTIS LAXA; ELASTIC TISSUE; FEMALE; GELSOLIN; HUMANS; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; SKIN;

EID: 14844296958     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06276.x     Document Type: Article

References (46)

1. Meretoja J. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes, and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1969; 1:314-24.
2. Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF) and its variants found worldwide. A review. Amyloid 1998; 5:55-66.
3. Stewart HS, Parveen R, Ridgeway AE et al. Late onset lattice corneal dystrophy with systemic familial amyloidosis, amyloidosis V, in an English family. Br J Ophthalmol 2000; 84:390-4.
4. Conceicao I, Sales-Luis ML, de Carvalho M et al. Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family; clinical and neurophysiological studies. Muscle Nerve 2003; 28:715-21.
5. Kiuru S, Salonen O, Haltia M. Gelsolin-related spinal and cerebral amyloid angiopathy. Ann Neurol 1999; 45:305-11.
6. Levy E, Haltia M, Fernandez-Madrid I et al. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 1990; 172:1865-7.
7. De la Chapelle A, Tolvanen R, Boysen G et al. Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet 1992; 2:157-60.
8. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 1999; 11:103-8.
9. 2+ stabilization. EMBO J 2001; 20:6277-87.
10. Ghiso J, Haltia M, Prelli F et al. Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type. Biochem J 1990; 272:827-30.
11. Haltia M, Ghiso J, Prelli F et al. Amyloid in familial amyloidosis, Finnish type, is antigenically and structurally related to gelsolin. Am J Pathol 1990; 136:1223-8.
12. Kazmirski SL, Howard MJ, Isaacson RL, Fersht AR. Elucidating the mechanism of familial amyloidosis - Finnish type: NMR studies of human gelsolin domain 2. Proc Natl Acad Sci USA 2000; 97:10706-11.
13. Robinson RC, Choe S, Burtnick LD. The disintegration of a molecule: the role of gelsolin in FAF, familial amyloidosis (Finnish type). Proc Natl Acad Sci USA 2001; 98:2117-18.
14. Westberg JA, Zhang K-Z, Andersson LC. Regulation of neural differentiation by normal and mutant (G654A, amyloidogenic) gelsolin. FASEB J 1999; 13:1621-6.
15. Kiuru S, Javela K, Somer H, Kekomäki R. Altered platelet shape change in hereditary gelsolin Asp187 Asn-related amyloidosis. Thromb Haemost 2000; 83:491-5.
16. Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol 1988; 18:1-16.
17. Lee D-D, Huang C-Y, Wong C-K. Dermatopathological findings in 20 cases of systemic amyloidosis. Am J Dermatopathol 1998; 20:438-42.
18. Touart DM, Sau P. Cutaneous deposition diseases. Part I. J Am Acad Dermatol 1998; 39:149-71.
19. Rintala AE, Alanko A, Mäkinen J et al. Primary hereditary systemic amyloidosis (Meretoja's syndrome): clinical features and treatment by plastic surgery. Scand J Plast Reconstr Surg 1988; 22:141-5.
20. Uitto J, Pulkkinen L. Heritable diseases affecting the elastic tissue: cutis laxa, pseudoxanthoma elasticum and related disorders. In: Emery and Rimoin's Principles and Practice of Medical Genetics (Rimoin DL, Connor JM, Pyeritz KE, Korf BR, eds), 4th edn. New York: Churchill Livingstone, 2002; 4044-68.
21. Witke W, Sharpe AH, Hartwig JH et al. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 1995; 81:41-51.
22. Kangas H, Ulmanen I, Paunio T et al. Functional consequences of amyloidosis mutation for gelsolin polypeptide - analysis of gelsolin-actin interaction and gelsolin processing in gelsolin knock-out fibroblasts. FEBS Lett 1999; 454:233-9.
23. Paunio T, Kiuru S, Hongell V et al. Solid-phase minisequencing test reveals Asp 187 → Asn (G654 → A) mutation of gelsolin in all affected individuals with Finnish type of familial amyloidosis. Genomics 1992; 13:237-9.
24. Asl LH, Liepnieks JJ, Asl KH et al. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol 1999; 154:221-7.
25. Rubinow A, Cohen A. Skin involvement in generalized amyloidosis. A study of clinically involved and uninvolved skin in 50 patients with primary and secondary amyloidosis. Ann Intern Med 1978; 88:781-5.
26. 2- microglobulin amyloidosis following short-term hemodialysis. Am J Dermatopathol 1994; 16:179-84.
27. Rubinow A, Cohen AS. Skin involvement in familial amyloidotic polyneuropathy. Neurology 1981; 31:1341-5.
28. Benedikz E, Blöndal H, Gudmundsson G. Skin biopsies in hereditary cystatin C amyloidosis. Virchows Arch A Pathol Anat 1990; 417:325-31.
29. Newton JA, McKee PH, Black MM. Cutis laxa associated with amyloidosis. Clin Exp Dermatol 1986; 11:87-91.
30. Yoneda K, Kanoh T, Nomura S et al. Elastolytic cutaneous lesions in myeloma-associated amyloidosis. Arch Dermatol 1990; 126:657-60.
31. Kiuru S, Nieminen T, Partinen M. Obstructive sleep apnoea in hereditary gelsolin-related amyloidosis. J Sleep Res 1999; 8:143-9.
32. Meretoja J, Teppo L. Histopathological findings of familial amyloidosis with cranial neuropathy as principal manifestation. Acta Pathol Microbiol Scand 1971; 79:432-40.
33. Kiuru-Enari S, Somer H, Seppäläinen A-M et al. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol 2002; 61:565-71.
34. Sepp N, Pichler E, Breathnach SM et al. Amyloid elastosis: analysis of the role of amyloid P component. J Am Acad Dermatol 1990; 22:27-34.
35. Vecchietti G, Masouyé I, Salomon D et al. An unusual form of primary systemic amyloidosis: amyloid elastosis: report of a case treated by haematopoietic cell transplantation. Br J Dermatol 2003; 148:154-9.
36. Hicks BC, Weber PJ, Hashimoto K et al. Primary cutaneous amyloidosis of the auricular concha. J Am Acad Dermatol 1988; 18:19-25.
37. Breathnach SM, Melrose SM, Bhogal B et al. Immunohistochemical studies of amyloid P component in disorders of cutaneous elastic tissue. Br J Denratol 1982; 107:443-52.
38. Pepys MB, Booth DR, Hutchinson WL et al. Amyloid P component. A critical review. Amyloid 1997; 4:274-95.
39. Pepys MB, Herbert J, Hutchinson WL et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417:254-9.
40. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-51.
41. Tassabehij M, Metcalfe K, Hurst J et al. An elastin gene mutation producing abnormal tropoelastin and abnormal elastic fibers in a patient with autosomal dominant cutis laxa. Hum Mol Genet 1998; 7:1021-8.
42. Zhang MC, He L, Giro M et al. Cutis laxa arising from frameshift mutations in exon 30 of the elastin gene (ELN). J Biol Chem 1999; 274:981-6.
43. Loyes B, van Maldergem L, Mortier G et al. Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. Hum Mol Genet 2002; 11:2113-18.
44. Markova D, Zou Y, Ringpfeil F et al. Genetic heterogeneity of cutis laxa: a heterogeneous tandem duplication within fibulin-5 (FBLN5) gene. Am J Hum Genet 2003; 72:998-1004.
45. Weeds AG, Gooch J, McLaughlin P, Maury CPJ. Variant plasma gelsolin responsible for familial amyloidosis (Finnish type) has defective actin severing activity. FEBS Lett 1993; 335:119-23.
46. Bellotti V, Mangione P, Merlini G. Immunoglobulin light chain amyloidosis. The archetype of structural and pathogenic variability. J Struct Biol 2000; 130:280-9.